ST
FPRX

Spot Trading’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Spot Trading’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-5,000
Closed -$207K – 3696
2016
Q2 		$207K Buy
+5,000
New +$217K ﹤0.01% 2196
2016
Q1 		– Sell
-20,000
Closed -$830K – 4188
2015
Q4 		$830K Hold
20,000
– – 0.01% 1590
2015
Q3 		$308K Buy
+20,000
New +$430K ﹤0.01% 2388

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Spot Trading's FPRX Position: Q3 2016 in Review

Spot Trading sold out of Five Prime Therapeutics, Inc. (FPRX) in Q3 2016, closing a stake of 600 shares — an estimated $25K sold.

Spot Trading first reported a position in FPRX in Q3 2015 and held it in 3 quarters. The position peaked at $146K in Q3 2015. 176 funds tracked by Wall St. Rank hold FPRX as of Q3 2016.

  • Spot Trading reported no remaining Five Prime Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
  • Spot Trading sold 600 Five Prime Therapeutics, Inc. shares in Q3 2016, an estimated $25K.
  • Spot Trading first reported a position in Five Prime Therapeutics, Inc. in Q3 2015 and held it in 3 quarters.
  • Spot Trading's Five Prime Therapeutics, Inc. position peaked at $146K in Q3 2015.
  • 176 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q3 2016.

Based on Spot Trading's 13F filing for Q3 2016, filed 31 Oct 2016.